Literature DB >> 31770128

Rapid Induction of Buprenorphine/Naloxone for Chronic Pain Using a Microdosing Regimen: A Case Report.

Danny S Lee1,2, Jessica E Hann1,3, Sukhpreet S Klaire1, Mohammadali Nikoo4, Michael D Negraeff5, Pouya Rezazadeh-Azar1,6,7,8,9.   

Abstract

Buprenorphine is an effective treatment for chronic pain and may reduce opioid-induced hyperalgesia. However, its pharmacological properties make its induction challenging, time-consuming, and can precipitate opioid withdrawal. We present the case of a 66-year-old woman with inadequately controlled postoperative pain despite escalating doses of oxycodone and methadone, who was successfully transitioned to buprenorphine/naloxone using a rapid microinduction technique without precipitating opioid withdrawal. Rapid induction provides an alternative method for transitioning patients from other opioids to buprenorphine/naloxone and facilitates transition of patients with chronic pain to buprenorphine therapy within a shorter window compared to currently existing protocols.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31770128      PMCID： PMC7147949          DOI： 10.1213/XAA.0000000000001138

Source DB:  PubMed          Journal:  A A Pract        ISSN： 2575-3126


  13 in total

Review 1.  Pharmacokinetics of the combination tablet of buprenorphine and naloxone.

Authors:  C Nora Chiang; Richard L Hawks
Journal:  Drug Alcohol Depend       Date:  2003-05-21       Impact factor: 4.492

Review 2.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2014-02-06

3.  Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs.

Authors:  Donna A Volpe; Grainne A McMahon Tobin; R Daniel Mellon; Aspandiar G Katki; Robert J Parker; Thomas Colatsky; Timothy J Kropp; S Leigh Verbois
Journal:  Regul Toxicol Pharmacol       Date:  2011-01-06       Impact factor: 3.271

4.  Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series.

Authors:  Sukhpreet Klaire; Rebecca Zivanovic; Skye Pamela Barbic; Raman Sandhu; Nickie Mathew; Pouya Azar
Journal:  Am J Addict       Date:  2019-03-22

Review 5.  Spotlight on buprenorphine/naloxone in the treatment of opioid dependence.

Authors:  Jennifer S Orman; Gillian M Keating
Journal:  CNS Drugs       Date:  2009-10       Impact factor: 5.749

Review 6.  The Clinical Opiate Withdrawal Scale (COWS).

Authors:  Donald R Wesson; Walter Ling
Journal:  J Psychoactive Drugs       Date:  2003 Apr-Jun

7.  Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method.

Authors:  Robert Hämmig; Antje Kemter; Johannes Strasser; Ulrich von Bardeleben; Barbara Gugger; Marc Walter; Kenneth M Dürsteler; Marc Vogel
Journal:  Subst Abuse Rehabil       Date:  2016-07-20

8.  Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults - United States, 2016.

Authors:  James Dahlhamer; Jacqueline Lucas; Carla Zelaya; Richard Nahin; Sean Mackey; Lynn DeBar; Robert Kerns; Michael Von Korff; Linda Porter; Charles Helmick
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-09-14       Impact factor: 17.586

Review 9.  CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016.

Authors:  Deborah Dowell; Tamara M Haegerich; Roger Chou
Journal:  JAMA       Date:  2016-04-19       Impact factor: 56.272

10.  American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use.

Authors:  Kyle Kampman; Margaret Jarvis
Journal:  J Addict Med       Date:  2015 Sep-Oct       Impact factor: 3.702
View more
  7 in total

Review 1.  Treating Chronic Pain with Buprenorphine-The Practical Guide.

Authors:  Amy A Case; Justin Kullgren; Sidra Anwar; Sandra Pedraza; Mellar P Davis
Journal:  Curr Treat Options Oncol       Date:  2021-11-18

2.  Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial.

Authors:  Nickie Mathew; Pouya Azar; James S H Wong; Mohammadali Nikoo; Jean N Westenberg; Janet G Suen; Jennifer Y C Wong; Reinhard M Krausz; Christian G Schütz; Marc Vogel; Jesse A Sidhu; Jessica Moe; Shane Arishenkoff; Donald Griesdale
Journal:  Addict Sci Clin Pract       Date:  2021-02-12

3.  Remote buprenorphine-naloxone initiation as an essential service for people with chronic pain and opioid dependence during the COVID-19 pandemic: Case reports, clinical pathways, and implications for the future.

Authors:  Hance Clarke; Aliza Weinrib; Yuvaraj Kotteeswaran; Joel Katz; Alvis Yu; Robert Tanguay
Journal:  Can J Pain       Date:  2020-09-15

Review 4.  The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder.

Authors:  Joao P De Aquino; Suprit Parida; Mehmet Sofuoglu
Journal:  Clin Drug Investig       Date:  2021-04-05       Impact factor: 2.859

5.  Evaluation of Buprenorphine Rotation in Patients Receiving Long-term Opioids for Chronic Pain: A Systematic Review.

Authors:  Victoria D Powell; Jack M Rosenberg; Avani Yaganti; Claire Garpestad; Pooja Lagisetty; Carol Shannon; Maria J Silveira
Journal:  JAMA Netw Open       Date:  2021-09-01

Review 6.  Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review.

Authors:  Lauren A Spreen; Emma N Dittmar; Kyle C Quirk; Michael A Smith
Journal:  Pharmacotherapy       Date:  2022-03-25       Impact factor: 6.251

7.  Factors that distinguish opioid withdrawal during induction with buprenorphine microdosing: a configurational analysis.

Authors:  Adams K K; Miech E J; Sobieraj D M
Journal:  Addict Sci Clin Pract       Date:  2022-10-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.